European Journal of Clinical Pharmacology

, Volume 32, Issue 4, pp 411–418 | Cite as

Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients

  • L. J. Schaaf
  • B. R. Dobbs
  • I. R. Edwards
  • D. G. Perrier
Originals

Summary

The nonlinear disposition kinetics of 5-fluorouracil (5-FU) were investigated in 6 patients with colorectal carcinoma. Each patient randomly received two single, intravenous doses of 5-FU (7.5 and 15 mg/kg) on separate days. Venous blood and urine samples were collected just prior to and for 5 h after drug administration. In addition to the kinetic studies, the in vitro whole blood/plasma concentration ratio and stability of 5-FU at 37°C were determined in whole blood from normal volunteers and from 5 patients with colorectal carcinoma.

A disproportionate increase in area under the curve and corresponding decrease in total body clearance with increasing dose was observed suggesting dose-dependent behavior of 5-FU. Doubling the dose was accompanied by a 36% decrease in nonrenal clearance but no apparent change in renal clearance. Therefore, the mechanism for dose-dependent elimination appears to be primarily associated with nonrenal processes. The mean 5-FU half-life following the high dose was nearly twice as long as that observed for the low dose (12.3 versus 6.2 min). The log-linear decline in plasma concentrations and increase in half-life with dose suggest the potential role of product-inhibition as an explanation for the observed nonlinearity in 5-FU elimination.

The present study demonstrates that 5-FU degrades when incubated in whole blood. This most likely reflects metabolism in red blood cells or other blood-formed elements since 5-FU was stable in plasma. Although degradation in whole blood occurs, the estimated whole blood clearance does not contribute significantly to the observed total body clearance value. These findings suggest the possibility of pulmonary clearance of 5-FU.

Key words

5-fluorouracil colorectal carcinoma pharmacokinetics product-inhibition blood clearance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Myers C (1981) The pharmacology of the fluropyrimidines. Pharmacol Rev 33: 1–15Google Scholar
  2. 2.
    Gustavsson B, Hafstrom L (1981) Adjuvant and pallative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review. Acta Chir Scand [Suppl] 504: 1–28Google Scholar
  3. 3.
    Collins J, Dedrick R, King F, Speyer J, Myers C (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin Pharmacol Ther 28: 235–246Google Scholar
  4. 4.
    Spector W (1956) Handbook of biological data. Saunders, Philadelphia, p 279Google Scholar
  5. 5.
    Schaaf L, Ferry D, Hung C, Perrier D, Edwards IR (1985) Analysis of 5′-deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatography. J Chromatogr 342: 303–313Google Scholar
  6. 6.
    Benet L, Galeazzi R (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074Google Scholar
  7. 7.
    Perrier D, Mayersohn M (1982) Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 71: 372–373Google Scholar
  8. 8.
    Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558Google Scholar
  9. 9.
    Lam F, Longnecker M (1983) A modified Wilcoxon rank sum test for paired data. Biometrika 70: 510–513Google Scholar
  10. 10.
    Bradley S, Ingelfinger F, Bradley G (1952) Hepatic circulation in cirrhosis of the liver. Circulation 5: 419–429Google Scholar
  11. 11.
    Finch R, Bending M, Lant A (1979) Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients. Br J Clin Pharmacol 7: 613–617Google Scholar
  12. 12.
    Cadman E, Heimer R, Davis L (1979) Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 205: 1135–1137Google Scholar
  13. 13.
    Garrett E, Hurst G, Green J Jr (1977) Kinetics and mechanisms of drug action on microorganisms XXIII: Microbial kinetic assay for fluorouracil in biological fluids and it's application to human pharmacokinetics. J Pharm Sci 66: 1422–1429Google Scholar
  14. 14.
    Wagner J, Gyves J, Stetson P, Walker-Andrews S, Wollner I, Cochran M, Ensminger W (1986) Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res 46: 1499–1506Google Scholar
  15. 15.
    Gibaldi M, Perrier D (1982) Nonlinear pharmacokinetics. In: Swarbrick J (ed) Pharmacokinetics, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
  16. 16.
    Perrier D, Ashley J, Levy G (1973) Effect of product inhibition on kinetics of drug elimination. J Pharmacokinet Biopharm 1: 231–242Google Scholar
  17. 17.
    Mukherjee K, Heidelberger C (1960) Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 235: 433–437Google Scholar
  18. 18.
    Aubert C, Cano J, Rigault J, Seitz J, Carcassonne Y (1981) Pharmacokinetics of 5-fluorouracil: Impact of the measurement of the 5,6-dihydrofluorouracil. Bull Cancer 68: 343–345Google Scholar
  19. 19.
    Aubert C, Sommadossi J, Coasslo P, Cano J, Rigault J (1982) Quantitative analysis of 5-fluorouracil and 5,6-dihydrofluorouracil in plasma by gas chromatography mass spectrometry. Biomed Mass Spectrom 9: 336–339Google Scholar
  20. 20.
    Benet L, Massoud N (1984) Pharmacokinetics. In: Benet L, Massoud N, Gambertoglio J (eds) Pharmacokinetic basis for drug treatment. Raven Press, New YorkGoogle Scholar
  21. 21.
    Jusko W, Gibaldi M (1972) Effects of change in elimination on various parameters of the two-compartment open model. J Pharm Sci 61: 1270–1273Google Scholar
  22. 22.
    Celio L, DiGregorio G, Ruch E, Pace J, Piraino A (1983) Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. Eur J Clin Pharmacol 24: 261–266Google Scholar
  23. 23.
    Diem K, Lentner C (eds) (1970) In: Documenta Geigy, 7th edn. Ciba-Geigy, Basle, SwitzerlandGoogle Scholar
  24. 24.
    Lam F, Hung C, Perrier D (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 74: 229–231Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • L. J. Schaaf
    • 1
  • B. R. Dobbs
    • 2
  • I. R. Edwards
    • 2
  • D. G. Perrier
    • 1
  1. 1.Department of PharmacyUniversity of Otago Medical SchoolDunedinNew Zealand
  2. 2.Medical Research Council of New Zealand, Toxicology Research UnitUniversity of Otago Medical SchoolDunedinNew Zealand

Personalised recommendations